09:35 AM EST - WPD Pharmaceuticals Inc. : Announced that is has engaged world-renowned Contract Research Organization (“CRO”), Worldwide Clinical Trials (“WCT”) to coordinate and supervise Phase 1 and 2 clinical trials on its Berubicin drug candidate. Berubicin is a new drug and one of the first anthracyclines proven to cross the blood-brain barrier to reach brain tumors. The discovery and further development of Berubicin can potentially extend the clinical use of anthracyclines to brain tumors, specifically Glioblastoma, an aggressive type of cancer that can occur in the brain or spinal cord. WPD Pharmaceuticals Inc.
shares C.WBIO are trading up 3.13 percent at $0.33.
